3 Stocks Pop, Drop, and Plunge

At almost the hallway point of the year, health care has been far and away the top performing sector.  However, that doesn’t mean that volatility has left the biotech portion of the industry. Here are three stocks that dominated the action in today’s trading session.

The Pop

Shares of Alexza Pharmaceuticals (Nasdaq: ALXA  ) soared 28% on news that it was resubmitting Adasuve for FDA approval. Efficacy was never the question for Adasuve -- the inhaled antipsychotic drug received a 17 to 1 vote from an advisory committee confirming its effectiveness. The red flag was always safety, as patients saw a decrease in lung function. Alexza insisted that the concerns in the CRL were “readily addressable,” and this swift resubmission is a testament to that.

If Adasuve is approved, it will face competition from injected treatments  like Eli Lilly's (NYSE: LLY  ) Zyprexa and Pfizer's Geodon, that may still be used first, depending on circumstances and labeling. And if it isn’t approved, investors should question whether Alexza management truly understands what it takes to bring this drug to market.

The Drop

It’s almost shocking to witness Arena Pharmaceuticals (Nasdaq: ARNA  ) posting a 15% decline, considering that the stock seemingly does nothing but go up. Shares are a five-bagger in 2012, including a whopping 62% increase in the last month alone. With a massive binary event looming large on June 27th -- the potential approval of obesity drug lorcaserin -- today’s sell-off is likely nothing more than sensible profit taking ahead of the weekend.

Investors in competitor VIVUS (Nasdaq: VVUS  ) will be watching what happens to lorcaserin with intense interest. VIVUS’ drug Qnexa’s date with the FDA was pushed back to later this summer, but an approval for Arena could indicate that the FDA has softened its stance, and send VIVUS shares higher, even though it would be second to market.

I want to caution investors who are not currently invested to stay away from Arena for the time being. Although an approval is considerably more likely than I would have guessed six months ago, lorcaserin is Arena’s only late stage drug, and a rejection would be devastating.

The Plunge

Today was not good for Theratechnologies (Nasdaq: THER  ) investors. Shares of the microcap plunged nearly 60% after giving a regulatory update on tesamorelin. The drug, which combats abdominal fat in HIV sufferers, had its European application for approval pulled by Theratech’s partner, Ferrer. Unlike the FDA, the EMA/CHMP allows companies to withdraw drugs if approval is known to be unlikely, before an outright rejection is issued. Celgene exercised that option with an expanded indication for Revlimid earlier this week. The company has indicated that it will not be EBITDA positive next year, and has withdrawn guidance for the time being. It seems challenging times are ahead for Theratechnologies.

Health-care investors are always looking for the next big breakthrough, and Motley Fool co-founder David Gardner recently identified a small-cap health-care company that’s poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

David Williamson owns shares of Pfizer, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 02, 2012, at 7:19 PM, PatentEye wrote:

    Yes, completely agree with your analysis on Theratechnologies. One of the big factors most people are missing with this company is that the EGRIFTA product (the one rejected by the EMA) carries what seems to be a large amount of patent risk; the company has only four patent families that protect EGRIFTA, and three of those four families are very weak. The only strong member is due to expire in less than four years. Obviously, this leads to a pretty poor outlook for the stock.

    If anyone is interested, there is a much more detailed analysis of the stock which is available for free here: http://www.scribd.com/doc/115172029/THER-by-Patent-Eye

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1922081, ~/Articles/ArticleHandler.aspx, 10/22/2014 9:01:43 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement